Wegovy Pill UK
Wegovy Pill UK: Approval, Cost and Availability Explained
The plain English UK guide to oral Wegovy: how the once-daily semaglutide tablet works, OASIS-4 results, dosing, side effects, NHS status and how it compares with the injection.
What is the Wegovy pill?
The Wegovy pill is a once-daily tablet containing semaglutide, the same active ingredient used in Wegovy injections. The MHRA authorised it on 11 June 2026 as the UK’s first GLP-1 receptor agonist tablet specifically approved for weight loss and weight management.
It is licensed alongside a reduced-calorie diet and increased physical activity for adults with obesity, meaning a BMI of at least 30, or adults who are overweight with a BMI from 27 to below 30 and at least one weight-related health condition.
The tablet starts at 1.5mg once daily for one month, then normally increases to 4mg, 9mg and finally the 25mg daily maintenance dose, with at least one month at each dose level. A prescriber can keep someone at the previous dose for longer if needed.
Unlike the weekly injection, oral Wegovy has strict administration instructions because food, water and other tablets can affect how much semaglutide is absorbed. It is a prescription-only medicine and should be prescribed after an appropriate clinical assessment.
What did the OASIS-4 trial actually show?
OASIS-4 is the key Phase 3b trial behind the UK approval of Wegovy 25mg tablets for weight management. It included 307 adults without diabetes who had obesity, or overweight plus at least one weight-related complication. Participants received oral semaglutide 25mg or placebo alongside lifestyle intervention.
At week 64, average weight change in the primary treatment-policy analysis was -13.6 percent with oral semaglutide compared with -2.2 percent with placebo. In the semaglutide group, 76.3 percent lost at least 5 percent of their starting weight, 59.8 percent lost at least 10 percent, 47.0 percent lost at least 15 percent and 27.5 percent lost at least 20 percent.
You may also see a 16.6 percent figure quoted for the Wegovy pill. That comes from the trial’s efficacy estimand, which estimates the treatment effect if participants remained on treatment. It should not simply be described as a separate group of ‘fully adherent patients’, and it should not be compared directly with percentages from other trials unless the estimands and populations are also considered.
OASIS-4 also found improvements in measures including waist circumference and physical functioning. These are group averages from a controlled clinical trial, not a prediction of how much any individual will lose.
Wegovy Pill UK vs Wegovy injections
Both versions of Wegovy contain semaglutide, but the way they are taken is very different.
The injection is taken once weekly. The tablet is taken once every day and needs a consistent fasting routine. The UK patient leaflet says to take it after fasting for at least 8 hours, swallow one tablet whole with a small amount of water, up to 120mL, and then wait at least 30 minutes before eating, drinking or taking other oral medicines. The tablet should not be split, crushed or chewed.
The weekly injection does not have those fasting instructions, so the tablet is not automatically the more convenient option simply because it avoids a needle. Some people may prefer a daily tablet; others may find a weekly injection easier to fit around everyday life.
Patients taking semaglutide injection 2.4mg once weekly can be transitioned to the 25mg tablet once daily under their prescriber’s direction. However, the UK product information specifically warns that the effect of switching cannot easily be predicted because absorption of oral semaglutide is more variable than with the injection.
There is no direct trial proving that 25mg oral Wegovy and 2.4mg injectable Wegovy produce identical weight loss. They should be treated as different formulations with their own evidence rather than assumed to be dose-for-dose equivalents.
Wegovy pill vs Wegovy injections vs Mounjaro – which should I choose?
The three treatments are not interchangeable, and their headline trial percentages should not be treated as a simple league table.
The Wegovy pill contains semaglutide and targets the GLP-1 receptor. In OASIS-4, 25mg oral semaglutide produced 13.6 percent average weight loss at week 64 in the primary treatment-policy analysis. Standard 2.4mg Wegovy injection produced 14.9 percent average weight loss at week 68 in STEP 1 under its treatment-policy estimand. The newer 7.2mg Wegovy injection produced greater weight loss in STEP UP, but the widely quoted 20.7 percent result is an efficacy-estimand figure.
Mounjaro contains tirzepatide and activates both GIP and GLP-1 receptors. It has produced larger average reductions in several obesity trials, and SURMOUNT-5 directly found 20.2 percent average weight loss with tirzepatide versus 13.7 percent with semaglutide 1.7mg or 2.4mg at 72 weeks. That trial did not test oral Wegovy or Wegovy 7.2mg.
There is therefore no direct head-to-head trial showing how the 25mg Wegovy tablet compares with Mounjaro or Wegovy 7.2mg. The practical choice depends on eligibility, medical history, tolerability, preferred dosing routine, availability, cost and prescriber assessment, not headline percentages alone. For a broader evidence comparison, see our weight loss jabs and pills compared guide.
Wegovy pill side effects – what we know so far
The safety profile in OASIS-4 was broadly consistent with what is already known about semaglutide. Gastrointestinal side effects were the most common: gastrointestinal adverse events occurred in 74.0 percent of participants receiving oral semaglutide versus 42.2 percent receiving placebo. Nausea, vomiting, constipation, diarrhoea and abdominal symptoms are all recognised effects, particularly while the dose is being increased.
Vomiting and diarrhoea can cause dehydration. Semaglutide can also cause gallstones or gallbladder inflammation, and people with diabetes may need additional consideration around diabetic retinopathy and medicines that can cause low blood sugar.
Acute pancreatitis is an uncommon but important risk. In January 2026, the MHRA strengthened warnings for GLP-1 medicines after rare reports of severe, necrotising and fatal pancreatitis. Severe and persistent abdominal pain, which may radiate to the back and may occur with nausea or vomiting, needs urgent medical attention. Treatment should be stopped if pancreatitis is suspected and not restarted if pancreatitis is confirmed.
In February 2026, the MHRA also updated semaglutide information to include the very rare eye condition NAION. Sudden loss or rapid worsening of vision needs urgent medical assessment.
Wegovy tablets should not be used during pregnancy. Semaglutide should be stopped at least two months before a planned pregnancy and should not be used while breast-feeding. Patients should also tell their medical team that they take Wegovy before surgery or procedures involving general anaesthesia or deep sedation because delayed stomach emptying can increase aspiration risk.
What will the Wegovy pill cost in the UK?
Private prices for oral Wegovy vary by dose and provider and can change frequently, so we do not hard-code a price range into this guide. See our Wegovy price comparison for the latest UK prices we have checked.
When comparing providers, look beyond the headline monthly price. Check which dose is included, whether consultation and follow-up are included, delivery charges, membership fees and whether an introductory offer changes after the first month.
The Wegovy tablet is MHRA-authorised for weight management, but the existing NICE semaglutide weight-management recommendation, TA875, predates the oral formulation and is based on the injectable product. We have not found a current NICE recommendation specifically establishing routine NHS weight-management access to the new 25mg Wegovy tablet, so this page does not speculate about a future NHS launch date.
Swipe sideways to see the full table →
|
Treatment |
Average Weight Loss |
Receptors Targeted |
UK Status |
Live Pricing |
|---|---|---|---|---|
|
Retatrutide |
28.3% |
3 (GLP-1 GIP Glucagon) |
Not approved |
Coming soon |
|
Mounjaro |
20.2% in SURMOUNT-5 |
2 (GLP-1 GIP) |
Approved |
|
|
Wegovy (injection) |
14.9% (2.4mg); up to 20.7% efficacy estimate (7.2mg) |
1 (GLP-1) |
Approved |
|
|
Ozempic |
Not licensed for weight loss |
1 (GLP-1) |
Diabetes only |
Coming soon |
|
CagriSema |
20.4% in REDEFINE 1 |
2 (GLP-1 Amylin) |
Not approved for weight management |
Coming soon |
|
Wegovy Pill |
13.6% in OASIS-4 |
1 (GLP-1) |
MHRA approved; NHS route not established |
Frequently Asked Questions
Is the Wegovy pill available in the UK?
The Wegovy semaglutide tablet was authorised by the MHRA on 11 June 2026 for weight management in eligible adults. It is a prescription-only medicine and private availability can vary between providers and doses.
When will the Wegovy pill be more widely available?
The tablet is already MHRA-authorised in the UK, but stock and provider availability can change. Rather than predicting future supply, check a regulated UK prescriber or our live Wegovy price comparison for current private availability.
Is the Wegovy pill as effective as injections?
OASIS-4 found 13.6 percent average weight loss with oral semaglutide 25mg at week 64 in the primary treatment-policy analysis. STEP 1 reported 14.9 percent with injectable semaglutide 2.4mg at week 68, but these were separate trials rather than a direct head-to-head comparison. The two formulations should not be assumed to be exactly equivalent.
Is Mounjaro better than the Wegovy pill?
There is no direct head-to-head trial of Mounjaro against the Wegovy 25mg tablet. Tirzepatide has produced larger average weight reductions in several obesity trials, but comparing percentages across separate trials has limitations. Choice of treatment should also consider eligibility, medical history, side effects, dosing preference, cost and prescriber assessment.
Will the NHS prescribe the Wegovy pill?
The Wegovy tablet is MHRA-authorised, but the existing NICE semaglutide weight-management recommendation, TA875, predates the oral formulation and is based on injectable Wegovy. We have not found a current NICE recommendation specifically establishing routine NHS weight-management access to the new 25mg tablet, so there is no reliable NHS launch date to give.
What are the side effects?
The most common side effects are gastrointestinal, including nausea, vomiting, diarrhoea, constipation and abdominal symptoms. Important less common risks include pancreatitis and gallbladder problems. Semaglutide has also been linked very rarely with NAION, an eye condition that can cause sudden vision loss. Severe persistent abdominal pain or sudden loss of vision needs urgent medical assessment.
Can I switch from Wegovy injections to the pill?
Patients taking semaglutide injection 2.4mg once weekly can be transitioned to semaglutide 25mg tablets once daily under a prescriber’s direction. However, the UK product information says the effect of switching cannot easily be predicted because oral semaglutide has greater variability in absorption than the injection.
About this page
Page reviewed 16 September 2026. Sources checked include the current UK Wegovy tablet SmPC and patient leaflet, the MHRA June 2026 approval, OASIS-4, MHRA pancreatitis and NAION safety updates, and current NICE semaglutide guidance. This guide is for information purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting, stopping or switching treatment.
Price comparison
Wegovy UK Price Comparison
Every UK clinic checked, so you can compare Wegovy prices before you sign up.
Key facts at a glance
Keep reading